Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Mar 11;57(3):257.
doi: 10.3390/medicina57030257.

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

Livius Tirnea  1 , Felix Bratosin  1 , Iulia Vidican  1 , Bianca Cerbu  1 , Mirela Turaiche  1 , Madalina Timircan  2 , Madalin-Marius Margan  3 , Iosif Marincu  1
Affiliations

The Efficacy of Convalescent Plasma Use in Critically Ill COVID-19 Patients

Livius Tirnea et al. Medicina (Kaunas). .

Abstract

Background and Objectives: On 24 March 2020, the United States Food and Drug Administration (FDA) announced the approval of convalescent plasma therapy for critically ill patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) as an emergency investigational new drug. This pilot study from Romania aimed to determine if convalescent plasma transfusion can be beneficial in the treatment of selected critically ill patients diagnosed with a SARS-CoV-2 infection. Materials and Methods: Donor and receiver eligibility for critically ill coronavirus disease 2019 (COVID-19) patients was based on Romanian guidelines issued at the time of the study. Here, we describe the evolution of a total of five eligible patients diagnosed with COVID-19 who received convalescent plasma (CP) in Romania. Results: In spite of our efforts and convalescent plasma administration, three of the five patients did not survive, while the other two recovered completely. Over the course of our five-day laboratory record, the surviving patients had significantly lower values for C-reactive protein, interleukin-6, and white blood cells. Conclusions: This pilot study provides insufficient evidence to determine the efficacy of convalescent plasma use as a therapeutic option for critically ill COVID-19 patients.

Keywords: COVID-19; SARS CoV-2; convalescent plasma; critically ill; transfusion.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Average values of laboratory findings in survivors and deceased patients.
See this image and copyright information in PMC

References

    1. Tanne J.H. Covid-19: FDA Approves the Use of Convalescent Plasma to Treat Critically Ill Patients. BMJ. 2020;386:m1256. doi: 10.1136/bmj.m1256. - DOI - PubMed
    1. Marano G., Vaglio S., Pupella S., Facco G., Catalano L., Liumbruno G.M., Grazzini G. Convalescent plasma: New evidence for an old therapeutic tool? Blood Transfus. 2016;14:152. - PMC - PubMed
    1. Chen L., Xiong J., Bao L., Shi Y. Convalescent plasma as a potential therapy for COVID-19. Lancet Infect. Dis. 2020;20:398–400. doi: 10.1016/S1473-3099(20)30141-9. - DOI - PMC - PubMed
    1. Metodologia Pentru Colectarea Testarea Procesarea Stocarea Si Distributia a Plasmei. The Romanian Ministry of Health, Bucharest, Romania. [(accessed on 22 April 2020)]; Available online: www.ms.ro:http://www.ms.ro/2020/04/22/metodologia-pentru-colectarea-test....
    1. Hung I.F., To K.K., Lee C.-K., Lee K.-L., Chan K., Yan W.-W., Liu R., Watt C.-L., Chan W.-M., Lai K.-Y., et al. Convalescent Plasma Treatment Reduced Mortality in Patients With Severe Pandemic Influenza A (H1N1) 2009 Virus Infection. Clin. Infect. Dis. 2011;52:447–456. doi: 10.1093/cid/ciq106. - DOI - PMC - PubMed

MeSH terms